ProQR Therapeutics - PRQR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 552.83 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$0.77
▲ +0.02 (2.68%)

This chart shows the closing price for PRQR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProQR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRQR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRQR

Analyst Price Target is $5.00
▲ +552.83% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $17.00 and a low forecast of $2.00. The average price target represents a 552.83% upside from the last price of $0.77.

This chart shows the closing price for PRQR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in ProQR Therapeutics. This rating has held steady since September 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
8/12/2022Raymond JamesUpgradeMarket Perform ➝ Outperform$2.00Low
8/12/2022Chardan CapitalDowngradeBuy ➝ NeutralLow
5/9/2022Cantor FitzgeraldReiterated RatingOverweightLow
5/9/2022HC WainwrightLower Target$4.00 ➝ $2.00High
4/19/2022Cantor FitzgeraldLower Target$6.00 ➝ $3.50Low
4/14/2022JMP SecuritiesLower TargetMarket Outperform$8.00 ➝ $5.00High
4/14/2022Chardan CapitalLower TargetBuy$8.00 ➝ $2.50High
2/14/2022Chardan CapitalLower TargetBuy$18.00 ➝ $8.00High
2/14/2022JMP SecuritiesLower TargetMarket Outperform$29.00 ➝ $8.00High
2/14/2022HC WainwrightLower TargetBuy$20.00 ➝ $4.00High
2/13/2022CitigroupDowngradeBuy ➝ HoldHigh
2/11/2022Raymond JamesDowngradeStrong-Buy ➝ Market PerformN/A
2/11/2022Stifel NicolausDowngradeBuy ➝ Hold$20.00 ➝ $3.00N/A
2/1/2022Raymond JamesInitiated CoverageStrong-Buy$19.00Medium
11/7/2021Evercore ISIReiterated RatingBuy$17.00Low
10/18/2021Cantor FitzgeraldReiterated RatingOverweightLow
9/30/2021JMP SecuritiesReiterated RatingBuy$31.00Low
9/12/2021Evercore ISIReiterated RatingBuyMedium
9/10/2021Chardan CapitalReiterated RatingBuy$18.00Medium
9/9/2021HC WainwrightReiterated RatingBuy$20.00High
9/9/2021JMP SecuritiesReiterated RatingBuy$31.00High
8/9/2021Chardan CapitalLower TargetBuy$20.00 ➝ $18.00Low
5/3/2021Stifel NicolausInitiated CoverageBuy$20.00Medium
3/25/2021CitigroupBoost Target$33.00 ➝ $44.00Medium
3/24/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$22.00 ➝ $33.00High
3/24/2021JMP SecuritiesBoost TargetOutperform$19.00 ➝ $35.00High
10/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
10/1/2020Cantor FitzgeraldReiterated RatingOverweightLow
8/11/2020Chardan CapitalLower TargetBuy$25.00 ➝ $20.00High
7/21/2020Chardan CapitalReiterated RatingBuy$25.00High
7/21/2020HC WainwrightReiterated RatingBuy$20.00High
6/23/2020Chardan CapitalReiterated RatingBuy$25.00Low
5/11/2020HC WainwrightReiterated RatingBuyHigh
4/1/2020Chardan CapitalReiterated RatingBuy$25.00High
10/11/2019Chardan CapitalReiterated RatingBuy$25.00High
10/10/2019CitigroupBoost TargetBuy$34.00 ➝ $40.00High
8/16/2019Chardan CapitalSet TargetBuy$25.00High
8/11/2019Royal Bank of CanadaReiterated RatingBuy$27.00Medium
3/12/2019Chardan CapitalReiterated RatingBuy ➝ Buy$21.00 ➝ $25.00High
2/28/2019HC WainwrightReiterated RatingBuy$20.00Medium
1/29/2019Cantor FitzgeraldSet TargetBuy$40.00Low
1/7/2019Chardan CapitalReiterated RatingBuy$21.00High
12/19/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ OutperformLow
12/13/2018Cantor FitzgeraldReiterated RatingBuy$40.00Medium
11/30/2018Cantor FitzgeraldSet TargetBuy$40.00High
11/15/2018CitigroupInitiated CoverageBuy ➝ Buy$32.00High
11/14/2018Cantor FitzgeraldReiterated RatingOverweightLow
11/13/2018Cantor FitzgeraldInitiated CoverageBuy$40.00High
10/30/2018HC WainwrightReiterated RatingBuy$20.00Medium
9/18/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$35.00Medium
8/13/2018Chardan CapitalReiterated RatingBuy$9.00Medium
8/9/2018HC WainwrightSet TargetBuy$20.00Medium
7/2/2018HC WainwrightReiterated RatingBuyLow
4/5/2018Chardan CapitalInitiated CoverageBuy$4.50Low
1/16/2018Chardan CapitalReiterated RatingNeutralLow
(Data available from 9/28/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
3/2/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/1/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/1/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/31/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/30/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
ProQR Therapeutics logo
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Read More

Today's Range

Now: $0.77
Low: $0.72
High: $0.77

50 Day Range

MA: $0.80
Low: $0.74
High: $0.89

52 Week Range

Now: $0.77
Low: $0.53
High: $9.09

Volume

466,005 shs

Average Volume

1,039,024 shs

Market Capitalization

$54.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of ProQR Therapeutics?

The following sell-side analysts have issued research reports on ProQR Therapeutics in the last year: Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Evercore ISI, HC Wainwright, JMP Securities, Raymond James, Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for PRQR.

What is the current price target for ProQR Therapeutics?

7 Wall Street analysts have set twelve-month price targets for ProQR Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 557.9%. Evercore ISI has the highest price target set, predicting PRQR will reach $17.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $2.00 for ProQR Therapeutics in the next year.
View the latest price targets for PRQR.

What is the current consensus analyst rating for ProQR Therapeutics?

ProQR Therapeutics currently has 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRQR will outperform the market and that investors should add to their positions of ProQR Therapeutics.
View the latest ratings for PRQR.

What other companies compete with ProQR Therapeutics?

How do I contact ProQR Therapeutics' investor relations team?

ProQR Therapeutics' physical mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company's listed phone number is (188) 166-7000 and its investor relations email address is [email protected] The official website for ProQR Therapeutics is www.proqr.com. Learn More about contacing ProQR Therapeutics investor relations.